Sunday Poster Session
Category: Functional Bowel Disease
Lin Chang, MD
University of California Los Angeles; G. Oppenheimer Center for Neurobiology of Stress and Resilience
Los Angeles, CA
Placebo | Linaclotide 290 μg | Placebo Vs Linaclotide 290 μg | ||||||
≤ 45 Years (N = 396) | > 45 Years (N = 401) | ≤ 45 Years (N = 396) | > 45 Years (N = 400) | ≤ 45 Years | > 45 Years | |||
n (%) | P-value | n (%) | P-value | P-value | ||||
Parameter | ||||||||
APC + 1 respondera | 59 (14.9) | 74 (18.5) | 0.1787 | 123 (31.1) | 139 (34.8) | 0.2684 | < 0.001 | < 0.001 |
30% improvement in abdominal pain for 50% of weeks responder | 124 (31.3) | 143 (35.7) | 0.1938 | 183 (46.2) | 200 (50.0) | 0.2852 | < 0.001 | < 0.001 |
Adequate relief of IBS symptoms for 50% of weeks responder | 112 (28.3) | 148 (36.9) | 0.0095 | 197 (49.7) | 236 (59.0) | 0.0088 | < 0.001 | < 0.001 |
Degree of relief of IBS symptoms overall responder | 61 (20.7)b | 60 (23.8)c | 0.3910 | 133 (44.9)d | 121 (45.5)e | 0.8948 | < 0.001 | < 0.001 |
aAPC +1 responder is defined as a patient who has an increase from baseline of at least 1 in the respective CSBM weekly rate and has a decrease from baseline of at least 30% in the respective weekly abdominal pain score; Some patient data were not captured: bn = 102 responses missing; cn = 149 responses missing; dn = 100 responses missing; en = 134 responses missing. APC, abdominal pain and constipation; CSBM, complete spontaneous bowel movement; IBS, irritable bowel syndrome. |